A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder (SNUGGLE)

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Urinary Bladder Neoplasms

Study type: Observational

Funder types: Industry

Identifiers

NCT05742867

CA209-6M4

Details and patient eligibility

About

The main purpose of this study is to identify important treatment attributes for post-radical cystectomy (RC) treatment for participants with MIBC (Muscle-Invasive Bladder Cancer) and assess the relative importance of treatment attributes for post-RC treatment in Japan.

Enrollment: 115 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must reside in Japan and able to speak/read Japanese for the interview/survey

• Must have a clinical diagnosis of Muscle-invasive bladder cancer (MIBC):

  • ypT2-ypT4a or ypN+ MIBC, with prior neoadjuvant cisplatin chemotherapy and underwent radical cystectomy
  • pT3-pT4a or pN+ MIBC, without prior neoadjuvant cisplatin chemotherapy and underwent radical cystectomy

• Must not have received any treatment related to MIBC after radical cystectomy

Exclusion criteria

• Determined by the physician as being unsuitable for the study (e.g. having any clinically significant psychiatric disorder, cognitive impairment, or having difficulty with communicating in Japanese)
• Confirmed diagnosis of other primary cancers at the time of obtaining consent
• Current participation in a MIBC clinical trial

Trial design

115 participants in 1 patient group

Cohort 1

Description:

High-risk Muscle-Invasive Bladder Cancer (MIBC) participants following radical cystectomy